鲁克索利提尼布在慢性骨髓增殖性新生体中的长期安全概况:全面的现实世界分析
Alberto Blanco-Sánchez1, Rosa Ayala1, Gonzalo Carreño-Tarragona1
1Hematology Department, Hospital 12 de Octubre, CNIO Complutense University Madrid Spain.
EJHaem
|October 31, 2025
概括
长期使用ruxolitinib治疗骨髓增殖性瘤与非黑色素瘤皮肤癌和诸如杆菌等感染的风险增加有关. 延长治疗没有提高二次恶性瘤的发病率,强调警.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 鲁克索利提尼布是对骨髓增殖性瘤的关键治疗方法.
- 虽然已知短期安全性,但长期毒性数据有限.
研究的目的:
- 评估长期 (≥3年) 卢克索利提尼布暴露的毒性.
- 评估非黑色素瘤皮肤癌 (NMSC),二次恶性瘤和感染的风险.
主要方法:
- 这是一项双队列回顾性研究,结合了本地队列和TriNetX现实世界数据库.
- 结果包括NMSC,其他二次恶性瘤和感染 (疹,尿道感染,肺炎,败血症).
- 倾向性得分匹配用于TrinetX队列.
主要成果:
- 在本地队列中,感染很常见 (72.2%),观察到晚发机会性感染.
- 在本地队列中发生了NMSC (19.4%) 和其他二次恶性瘤 (11.1%).
- 在TrinetX队列中,经过≥3年的 ruxolitinib,出现NMSC,,尿路感染,肺炎和败血症的风险增加.
结论:
- 延长鲁克索利提尼布治疗与特定的长期风险有关,特别是NMSC和子复激活.
- 长期使用时没有观察到二次恶性瘤的显著增加.
- 这些发现支持对长期使用ruxolitinib的患者进行持续监测和预防措施.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
193
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
193
Therapeutic Drug Monitoring: Overview and Classification
293
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
293
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
225
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
225
Bioavailability Study Design: Healthy Subjects Versus Patients
140
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
140
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
244
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
244


